Petosemtamab (MCLA-158) With Pembrolizumab as First-Line (1L) Treatment of PD-L1+ Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 2 Trial
June 25th 2025
Carla van Herpen, MD, PhD, presents phase 2 trial results showing that petosemtamab plus pembrolizumab in first-line PD-L1–positive recurrent/metastatic HNSCC achieved a 63% response rate, 9-month median PFS, and 79% 1-year OS, with durable responses and a favorable safety profile.